COVID-19 在多发性硬化症中的频率和严重程度：来自意大利北部的一个短期单站点报告。
Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy.
机构信息
Neurology Section - Department of Neurosciences, Biomedicine and Movement Sciences, University Hospital of Verona, Verona, Italy.
Medical Direction, University Hospital of Verona, Verona, Italy.
出版信息
Mult Scler Relat Disord. 2020 Sep;44:102372. doi: 10.1016/j.msard.2020.102372. Epub 2020 Jul 4.
Abstract
Neurologists are interested in understanding whether patients with multiple sclerosis (pwMS) undergoing immunomodulatory/immunosuppressive therapy are more susceptible to developing COVID-19 or have worse outcomes. Currently, there are no conclusive data in this regard. We report the prevalence and severity of COVID-19 (confirmed and possible) in pwMS followed at the Veneto Regional MS Center in Verona (Italy), an area most stricken by COVID-19. In our sample size, the prevalence of COVID-19 seems to be much higher than that officially reported at the regional level on the general population, but it also characterized by a favourable course.
摘要
神经病学家感兴趣的是了解接受免疫调节/免疫抑制治疗的多发性硬化症 (pwMS) 患者是否更容易感染 COVID-19 或出现更糟糕的结果。目前，这方面尚无确凿的数据。我们报告了在维罗纳的威尼托地区多发性硬化症中心（意大利）接受治疗的 pwMS 中 COVID-19（确诊和可能）的患病率和严重程度，该地区受 COVID-19 的影响最大。在我们的样本量中，COVID-19 的患病率似乎远高于该地区普通人群的官方报告，但它也具有良好的病程。
相似文献
1
Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy.
Mult Scler Relat Disord. 2020 Sep;44:102372. doi: 10.1016/j.msard.2020.102372. Epub 2020 Jul 4.
2
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.
3
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
4
Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada.
Mult Scler Relat Disord. 2022 Feb;58:103509. doi: 10.1016/j.msard.2022.103509. Epub 2022 Jan 8.
5
Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients.
J Med Virol. 2021 Mar;93(3):1314-1319. doi: 10.1002/jmv.26593. Epub 2020 Oct 30.
6
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.
7
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744. doi: 10.1002/acn3.51408. Epub 2021 Jul 7.
8
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Neurol Neurochir Pol. 2021;55(2):212-222. doi: 10.5603/PJNNS.a2021.0031. Epub 2021 Apr 15.
9
Multiple sclerosis, rituximab, and COVID-19.
Ann Clin Transl Neurol. 2021 Apr;8(4):938-943. doi: 10.1002/acn3.51342. Epub 2021 Mar 30.
10
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.
Mult Scler Relat Disord. 2020 Nov;46:102453. doi: 10.1016/j.msard.2020.102453. Epub 2020 Aug 19.
引用本文的文献
1
Neuropsychiatric symptoms associated with the COVID-19 and its potential nervous system infection mechanism: the role of imaging in the study.
Psychoradiology. 2021 Dec 22;1(4):199-211. doi: 10.1093/psyrad/kkab019. eCollection 2021 Dec.
2
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
J Clin Med. 2023 Nov 23;12(23):7243. doi: 10.3390/jcm12237243.
3
Multiple sclerosis and COVID-19: A retrospective study in Iran.
PLoS One. 2023 Mar 23;18(3):e0283538. doi: 10.1371/journal.pone.0283538. eCollection 2023.
4
Multiple sclerosis patients' response to COVID-19 pandemic and vaccination in Egypt.
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):131. doi: 10.1186/s41983-022-00573-8. Epub 2022 Nov 17.
5
Risk and prognostic factors for SARS-CoV-2 infection in Spanish population with multiple sclerosis during the first five waves.
Front Neurol. 2022 Oct 19;13:1001429. doi: 10.3389/fneur.2022.1001429. eCollection 2022.
6
Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East.
J Clin Neurosci. 2022 May;99:311-316. doi: 10.1016/j.jocn.2022.02.033. Epub 2022 Feb 24.
7
COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.
Mult Scler Relat Disord. 2022 Jan;57:103335. doi: 10.1016/j.msard.2021.103335. Epub 2021 Oct 16.
8
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.
Mult Scler Relat Disord. 2021 Oct;55:103217. doi: 10.1016/j.msard.2021.103217. Epub 2021 Aug 16.
9
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
10
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
Biomolecules. 2021 Jul 6;11(7):993. doi: 10.3390/biom11070993.
本文引用的文献
1
COVID-19 and MS disease-modifying therapies.
Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4). doi: 10.1212/NXI.0000000000000761. Print 2020 Jul.
2
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.
Mult Scler Relat Disord. 2020 Jul;42:102185. doi: 10.1016/j.msard.2020.102185. Epub 2020 May 7.
3
An Italian programme for COVID-19 infection in multiple sclerosis.
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
4
The COVID-19 pandemic and the use of MS disease-modifying therapies.
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
5
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
6
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
7
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
Zotero 插件